Security
SciSparc Ltd. Ordinary Shares · SPRC
SPRCNASDAQCommon stockCurrentCIK 1611746Updated Nov 21, 2026
SPRC price & chart
Loading TradingView…
NASDAQ:SPRC on TradingView ↗About the company
SciSparc Ltd. is undergoing a strategic transformation toward Agentic AI-powered technologies, with a focus on applications in cybersecurity and finance. Building on its decision to target the Agentic AI market and the establishment of a Scientific Advisory Board for AI and cybersecurity, the Company is evaluating technologies, companies and business opportunities across the Agentic AI ecosystem. Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks to achieve defined objectives.
In the news
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company ↗
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
cash flow · annual statements
| Line item | Q2 2018 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Profit or LossUSD | -1,214,000Source | -7,472,000Source | -5,883,000Source | -2,592,000Source | -5,789,000Source |
| Additional Financial Items | |||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | -50,000Source | 12,000Source | 55,000Source | 3,000Source | 170,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -101,000Source | 25,000Source | -397,000Source | — | 353,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 138,000Source | 569,000Source | 196,000Source | — | 43,000Source |
| GeneralAndAdministrativeExpenseUSD | 1,000,000Source | 4,526,000Source | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | — | 8,000Source | 7,000Source | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | 54,000Source | 47,000Source | — | — |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | 9,005,000Source | 7,699,000Source |
| ProceedsFromIssuingSharesUSD | — | 6,255,000Source | — | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | — | 4,861,000Source | — |
income statement · annual statements
| Line item | Q2 2022 | Q2 2018 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| Total RevenueUSD | — | — | 1,306,000Source | 2,879,000Source | 1,347,000Source | — |
| Additional Financial Items | ||||||
| ApplicableTaxRatenumber | — | — | — | 0.23Source | 0.23Source | 0.23Source |
| BasicEarningsLossPerShareUSD per share | — | — | 26.94Source | 14.43Source | — | 2.83Source |
| DilutedEarningsLossPerShareUSD per share | — | — | 26.94Source | 14.43Source | — | — |
| EmployeeBenefitsExpenseUSD | — | — | 106,000Source | 105,000Source | 115,000Source | 98,000Source |
| FinanceCostsUSD | — | 1,000Source | 353,000Source | 1,055,000Source | 2,014,000Source | 21,000Source |
| FinanceIncomeUSD | — | 437,000Source | 612,000Source | 2,219,000Source | 7,832,000Source | — |
| GeneralAndAdministrativeExpenseUSD | — | 1,000,000Source | 4,526,000Source | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| GrossProfitUSD | 10,210,000Source | — | 506,000Source | 2,196,000Source | 1,025,000Source | — |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | — | 1,344,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | — | -14,000Source | 22,000Source | 14,000Source | — |
| OtherIncomeUSD | — | — | 1,270,000Source | — | — | — |
| OtherOperatingIncomeExpenseUSD | — | — | — | — | -109,000Source | — |
| ProfitLossAttributableToNoncontrollingInterestsUSD | — | — | -1,188,000Source | -761,000Source | — | — |
| ProfitLossAttributableToOwnersOfParentUSD | — | — | -6,284,000Source | -5,122,000Source | 2,592,000Source | 5,789,000Source |
| ProfitLossBeforeTaxUSD | — | — | -7,486,000Source | -5,861,000Source | -2,578,000Source | — |
| ProfitLossFromOperatingActivitiesUSD | — | -1,650,000Source | -7,316,000Source | -6,815,000Source | -8,287,000Source | -5,768,000Source |
| ResearchAndDevelopmentExpenseUSD | — | 650,000Source | 1,707,000Source | 1,641,000Source | 2,803,000Source | 1,990,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | — | — | -429,000Source | -210,000Source | -109,000Source | — |
Offerings
Registration 333-299929
Registration 333-293533
Registration 333-293167
Filing attachments
ea031240801ex99-1.htm · 6-K · 2026-11-16
Exhibit 99.1 SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB Appointment of the former Head of Israel’s National Security Council and Former Acting National Security Advisor to Prime Minister Benjamin Netanyahu marks another step in laying the scientific and strategic foundation for SciSparc’s planned entry into the Agentic AI sector TEL AVIV, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: …
Read attachment ↗ea031140201ex4-1.htm · 6-K/A · 2026-11-09
Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A…
Read attachment ↗ea031140201ex4-2.htm · 6-K/A · 2026-11-09
Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED B…
Read attachment ↗ea031077601ex4-1.htm · 6-K · 2026-11-03
Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A…
Read attachment ↗ea031077601ex4-2.htm · 6-K · 2026-11-03
Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED B…
Read attachment ↗ea030941001ex99-1.htm · 6-K · 2026-10-23
Exhibit 99.1 SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has achieved further progress in its U.S. Food …
Read attachment ↗